tranScrip
Louise Whitley has extensive work experience in the medical and pharmaceutical field. Louise began their career with Lederle Laboratories in 1992 as the Acting Medical Information Manager. Afterwards, they worked with the Royal Pharmaceutical Society of Great Britain as the Senior Staff Editor BNF. In 1999, they joined the Southampton University Hospitals NHS Trust as a Medicines Information and Practice Pharmacist. Additionally, they worked as a freelance medical affairs, medical and regulatory writer, and also handled medical information and pharmacovigilance tasks. In 2011, they started working with tranScrip, initially as a Partner and later, as a Senior Partner. Presently, they hold the position of Executive Director of Medical Affairs and Safety at tranScrip.
Louise Whitley obtained a Bachelor of Science (BSc Hons) degree in Pharmacy from Aston University, from 1986 to 1989. Louise later pursued further education and obtained a Master of Science (MSc) degree in Clinical Pharmacy from the University of Brighton, from 1994 to 1996. Prior to their university education, Louise attended Dartford Grammar School for Girls, although the specific years are not provided.
This person is not in any offices
tranScrip
tranScrip is a leading contract drug development organisation which supports pharma and biotech companies in the development and lifecycle of medicines. We bring innovative solutions to clients’ global drug development needs. From translational medicine through to registration and post licencing, we deliver both strategic leadership and operational execution of development programmes, covering clinical, regulatory, drug safety, and commercial elements. Our teams of physicians, scientists and regulatory experts, help clients select the most promising drug candidates and bring them to the market. We guide our clients through their decision making from first in man studies to proof of concept and pivotal trials, regulatory submissions and product launches. In the last decade, tranScrip has supported over 250 clients and has been integral to many development programmes and regulatory submissions, bringing products to the market each year across a wide range of therapeutic areas.